{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:30:43Z","timestamp":1789504243293,"version":"build-2803163510"},"reference-count":17,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T00:00:00Z","timestamp":1607558400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"name":"BMS"},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013870","name":"Astex","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013870","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004628","name":"MedImmune","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004628","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Boehringer-Ingelheim"},{"name":"Trovagene"},{"name":"Incyte"},{"name":"Takeda"},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Aprea"},{"name":"ADC Therapeutics"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Trovagene"},{"name":"Taiho Oncology"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.clml.2020.12.002","type":"journal-article","created":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T09:12:27Z","timestamp":1607505147000},"page":"e248-e254","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Direct Medical Costs Associated With Treatment Nonpersistence in Patients With Higher-Risk Myelodysplastic Syndromes Receiving Hypomethylating Agents: A Large Retrospective Cohort Analysis"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5577-2890","authenticated-orcid":false,"given":"Namita","family":"Joshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hrishikesh","family":"Kale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4606-2971","authenticated-orcid":false,"given":"Shelby","family":"Corman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Wert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2657-5908","authenticated-orcid":false,"given":"Kala","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer M.","family":"Zeidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2020.12.002_bib1","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1182\/blood-2013-08-496935","article-title":"How we treat higher-risk myelodysplastic syndromes","volume":"123","author":"Sekeres","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.12.002_bib2","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2020.12.002_bib3","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.12.002_bib4","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.3747\/co.21.1311","article-title":"Cost-effectiveness in Canada of azacitidine for the treatment of higher-risk myelodysplastic syndromes","volume":"21","author":"Levy","year":"2014","journal-title":"Curr Oncol"},{"key":"10.1016\/j.clml.2020.12.002_bib5","first-page":"467","article-title":"Azacitidine in outpatient treatment\u2014single center experience","volume":"19","author":"Rybka","year":"2015","journal-title":"Contemp Oncol (Pozn)"},{"key":"10.1016\/j.clml.2020.12.002_bib6","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00520-014-2502-y","article-title":"Obstacles to adherence to azacitidine administration schedule in outpatient myelodysplastic syndrome and related disorders","volume":"23","author":"Tendas","year":"2015","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clml.2020.12.002_bib7","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12878-018-0095-2","article-title":"More is less, less is more, or does it really matter? The curious case of impact of azacitidine administration schedules on outcomes in patients with myelodysplastic syndromes","volume":"18","author":"Shallis","year":"2018","journal-title":"BMC Hematol"},{"key":"10.1016\/j.clml.2020.12.002_bib8","doi-asserted-by":"crossref","first-page":"60","DOI":"10.6004\/jnccn.2017.0007","article-title":"Myelodysplastic syndromes, version 2.2017, NCCN Clinical Practice Guidelines in Oncology","volume":"15","author":"Greenberg","year":"2017","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2020.12.002_bib9","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/ejh.12079","article-title":"Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia","volume":"90","author":"Voso","year":"2013","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2020.12.002_bib11","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1182\/blood-2017-10-811729","article-title":"Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation","volume":"131","author":"Zeidan","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.12.002_bib12","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/bjh.14305","article-title":"Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes","volume":"175","author":"Zeidan","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.12.002_bib13","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/10428194.2019.1663423","article-title":"Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents","volume":"61","author":"Zeidan","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2020.12.002_bib14","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.clml.2020.12.002_bib15","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1182\/blood-2018-99-111052","article-title":"Does provider experience treating patients (pts) with myelodysplastic syndromes (MDS) explain duration of hypomethylating agent (HMA) therapy and overall survival (OS)? A large population-based analysis","volume":"132","author":"Zeidan","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.12.002_bib16","series-title":"Treatment Patterns and Outcomes in Patients With Myelodysplastic Syndromes Treated With Hypomethylating Agents: A SEER-Medicare Analysis","author":"Stein","year":"2019"},{"key":"10.1016\/j.clml.2020.12.002_bib17","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1111\/j.1537-2995.2012.03626.x","article-title":"Economic impact on US Medicare of a new diagnosis of myelodysplastic syndromes and the incremental costs associated with blood transfusion need","volume":"52","author":"Goldberg","year":"2012","journal-title":"Transfusion"},{"key":"10.1016\/j.clml.2020.12.002_bib18","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1080\/10428194.2019.1703970","article-title":"Hypomethylating agent (HMA) therapy use and survival in older adults with refractory anemia with excess blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study","volume":"61","author":"Davidoff","year":"2020","journal-title":"Leuk Lymphoma"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020306698?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020306698?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T06:36:14Z","timestamp":1730529374000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265020306698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S2152265020306698"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2020.12.002","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Direct Medical Costs Associated With Treatment Nonpersistence in Patients With Higher-Risk Myelodysplastic Syndromes Receiving Hypomethylating Agents: A Large Retrospective Cohort Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2020.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}